Glucagon like Peptide 1 News and Research

RSS
Beyond the anti-obesity benefits of glucagon-like peptide-1 drugs

Beyond the anti-obesity benefits of glucagon-like peptide-1 drugs

Study identifies trends in the use of glucagon-like peptide-1 receptor agonists

Study identifies trends in the use of glucagon-like peptide-1 receptor agonists

Exploring the expanding horizons of GLP-1 therapies beyond diabetes and obesity

Exploring the expanding horizons of GLP-1 therapies beyond diabetes and obesity

Study shows oral semaglutide matches DPP-4i in adherence and persistence for type 2 diabetes

Study shows oral semaglutide matches DPP-4i in adherence and persistence for type 2 diabetes

Twincretin drug Tirzepatide shows unmatched efficacy in weight loss and diabetes management

Twincretin drug Tirzepatide shows unmatched efficacy in weight loss and diabetes management

AI analysis of Reddit reveals public interest in GLP-1 drugs for weight loss and mental health benefits

AI analysis of Reddit reveals public interest in GLP-1 drugs for weight loss and mental health benefits

New brain targets for GLP1-based obesity drugs may reduce weight without nausea

New brain targets for GLP1-based obesity drugs may reduce weight without nausea

Combined use of popular diabetes drugs likely to offer additional protection against heart and kidney disease

Combined use of popular diabetes drugs likely to offer additional protection against heart and kidney disease

Semaglutide and very-low calorie diet combo shows superior results in managing type 2 diabetes

Semaglutide and very-low calorie diet combo shows superior results in managing type 2 diabetes

Study reveals exercise and GLP-1 RA combination preserves bone health during weight loss

Study reveals exercise and GLP-1 RA combination preserves bone health during weight loss

Differences in effectiveness among antihyperglycemic drugs on dementia risk identified in recent study

Differences in effectiveness among antihyperglycemic drugs on dementia risk identified in recent study

New drug tirzepatide significantly improves sleep apnea and weight loss

New drug tirzepatide significantly improves sleep apnea and weight loss

Semaglutide reduces heart risks in overweight and obese individuals without diabetes

Semaglutide reduces heart risks in overweight and obese individuals without diabetes

Novo Nordisk presents key findings from semaglutide trials at ADA scientific sessions 2024

Novo Nordisk presents key findings from semaglutide trials at ADA scientific sessions 2024

Semaglutide weight loss results linked to diabetes severity

Semaglutide weight loss results linked to diabetes severity

WHO issues medical product alert on falsified semaglutides

WHO issues medical product alert on falsified semaglutides

Oral semaglutide proves effective for type 2 diabetes and weight loss in Dutch study

Oral semaglutide proves effective for type 2 diabetes and weight loss in Dutch study

Wegovy and Ozempic linked to reduced incidence and recurrence of alcohol abuse or dependence, study suggests

Wegovy and Ozempic linked to reduced incidence and recurrence of alcohol abuse or dependence, study suggests

Oral semaglutide shows significant promise in improving diabetes control and cardiovascular health, study reveals

Oral semaglutide shows significant promise in improving diabetes control and cardiovascular health, study reveals

GLP-1 receptor agonists effective for weight loss in obesity without diabetes

GLP-1 receptor agonists effective for weight loss in obesity without diabetes

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.